Cure8 research brief
The review suggests ginsenosides Rg1 and Rb1 may affect immune and metabolic pathways and the gut microbiome in ways relevant to IBD and related immune-metabolic diseases, which could guide future research toward new multi-target therapies.
Researchers studying IBD mechanisms or therapeutics, clinicians interested in experimental immunometabolic treatments, and scientists working on microbiome–host interactions and drug discovery.
This review integrates published experimental studies and computational analyses to propose mechanisms by which ginsenosides Rg1 and Rb1 could modulate gut barrier, immune signaling, metabolism, and the gut microbiome in conditions including IBD.
It describes candidate molecular pathways and microbial taxa potentially involved but does not present new clinical trial results. The paper uses network pharmacology and gut microbiota–host gene association methods to generate hypotheses (shared targets and taxa) rather than demonstrate causation.
Most evidence summarized is preclinical; the authors explicitly note a translational gap to clinical practice. If you are interested in ginseng compounds as multi-target therapeutics, this review offers a concise synthesis and computationally prioritized targets and taxa that could guide future laboratory or clinical research.
This article is an integrative review with computational analyses and summarizes largely preclinical evidence; it does not provide clinical trial data. Proposed mechanisms and microbiome links are hypothesis-generating and need experimental and clinical validation.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Peking University Third Hospital Fund for Interdisciplinary Research - BYSYJC2025060; Beijing Natural Science Foundation of China - J230002
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...
People with UC often use probiotics or microbiome-directed therapies alongside prescription drugs. Understanding probiotic–drug interactions could explain why individuals respond differently to IBD treatments and may...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
